Assessment of recombinant tissue plasminogen activator (rtPA) toxicity in cultured neural cells and subsequent treatment with poly-arginine peptide R18D-Reference-Cited by-同舟云学术

Assessment of recombinant tissue plasminogen activator (rtPA) toxicity in cultured neural cells and subsequent treatment with poly-arginine peptide R18D

Published:2020-03-05 Issue:5 Volume:45 Page:1215-1229
ISSN:0364-3190
Container-title:Neurochemical Research
language:en
Short-container-title:Neurochem Res

Author:

Kenna Jade E.,Anderton Ryan S.,Knuckey Neville W.,Meloni Bruno P.

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,General Medicine,Biochemistry

Link

http://link.springer.com/content/pdf/10.1007/s11064-020-03004-3.pdf

Reference56 articles.

1. Jovin TG, Nogueira RG, Investigators D (2018) Thrombectomy 6 to 24 hours after stroke. N Engl J Med 378(12):1161–1162. https://doi.org/10.1056/NEJMc1801530

2. Lees KR, Emberson J, Blackwell L, Bluhmki E, Davis SM, Donnan GA, Grotta JC, Kaste M, von Kummer R, Lansberg MG, Lindley RI, Lyden P, Murray GD, Sandercock PA, Toni D, Toyoda K, Wardlaw JM, Whiteley WN, Baigent C, Hacke W, Howard G, Stroke Thrombolysis Trialists' Collaborators G (2016) Effects of Alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials. Stroke 47(9):2373–2379. https://doi.org/10.1161/STROKEAHA.116.013644

3. Rao NM, Levine SR, Gornbein JA, Saver JL (2014) Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials. Stroke 45(9):2728–2733. https://doi.org/10.1161/STROKEAHA.114.005135

4. Chao AC, Hsu HY, Chung CP, Liu CH, Chen CH, Teng MM, Peng GS, Sheng WY, Hu HH, Taiwan Thrombolytic Therapy for Acute Ischemic Stroke Study G (2010) Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study. Stroke 41(5):885–890. https://doi.org/10.1161/STROKEAHA.109.575605

5. Ong CT, Wong YS, Wu CS, Su YH (2017) Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator. Drug Des Devel Ther 11:1559–1566. https://doi.org/10.2147/DDDT.S133759

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Matrix Metalloproteinases in Hemorrhagic Transformation in the Treatment of Stroke with Tissue Plasminogen Activator;Journal of Personalized Medicine;2023-07-23

2. Neuroprotective Effects of an Edible Pigment Brilliant Blue FCF against Behavioral Abnormity in MCAO Rats;Pharmaceuticals;2022-08-18

3. Exploring Contraindications for Thrombolysis: Risk of Hemorrhagic Transformation and Neurological Deterioration after Thrombolysis in Mice with Recent Ischemic Stroke and Hyperglycemia;Journal of Clinical Medicine;2022-06-10

4. Peptide5 Attenuates rtPA Related Brain Microvascular Endothelial Cells Reperfusion Injury via the Wnt/β-Catenin Signalling Pathway;Current Neurovascular Research;2021-10-21

5. Comparative Assessment of the Proteolytic Stability and Impact of Poly-Arginine Peptides R18 and R18D on Infarct Growth and Penumbral Tissue Preservation Following Middle Cerebral Artery Occlusion in the Sprague Dawley Rat;Neurochemical Research;2021-02-01